Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
New York, USA, May 09, 2024 (GLOBE NEWSWIRE) -- Psoriasis Vulgaris Clinical Trial Pipeline Analysis Demonstrates 50+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
The Psoriasis Vulgaris treatment market is expected to increase due to the increasing geriatric population across the globe. Advances in technology, heightened awareness of treatment options, and increased research and development efforts for Psoriasis Vulgaris treatments are all poised to boost market expansion.
DelveInsight's 'Psoriasis Vulgaris Pipeline Insight 2024' report provides comprehensive global coverage of pipeline psoriasis vulgaris therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the psoriasis vulgaris pipeline domain.
Key Takeaways from the Psoriasis Vulgaris Pipeline Report
- DelveInsight's psoriasis vulgaris pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for psoriasis vulgaris treatment.
- Key psoriasis vulgaris companies such as Xencor, Ono Pharmaceutical Co. Ltd, Boehringer Ingelheim, GC Cell Corporation, Soligenix, Cantargia AB, Huabo Biopharm, Huaota Biopharmaceuticals, Bio-Thera Solutions, Hangzhou Highlightll Pharmaceutical, Sanofi, Johnson & Johnson Innovative Medicine, Artax Biopharma, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Arxx Therapeutics, SFA Therapeutics, InventisBio, Beijing InnoCare Pharma Tech Co., LtdSun Pharmaceutical Industries Limited, E-nitiate Biopharmaceuticals, Meiji Pharma, and others are evaluating new psoriasis vulgaris drugs to improve the treatment landscape.
- Promising psoriasis vulgaris pipeline therapies such as XmAb564, BAT-2306, ONO-4685, BI 765250, CT303, SGX302, CAN10, HB0017, HOT-3010, TLL018, SAR441566, JNJ-2113, AX-158, SHR-1314, AX-202, SFA002, D-2570, ICP-488, SCD-044, QY101, ME3183, and others are under different phases of psoriasis vulgaris clinical trials.
- In March 2024, Alumis Inc. announced the presentation of positive clinical data from a Phase II clinical trial of ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate-to-severe plaque psoriasis. These data were presented during a late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting being held March 8-12 in San Diego, California.
- In February 2024, Biocon Biologics announced that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in the United States of America.
- In February 2024, Johnson & Johnson announced the publication in the New England Journal of Medicine (NEJM) of the Phase IIb FRONTIER 1 trial results for JNJ-2113. JNJ-2113 is the first and only investigational targeted oral peptide inhibitor designed to block the IL-23 receptor.
- In November 2023, Bio-Thera Solutions, Ltd. announced results from the Phase III study of BAT2206, a proposed biosimilar referencing Stelara (ustekinumab). The primary endpoint of this study was improvement from baseline in Psoriasis Area and Severity Index (PASI) score to Week 12, demonstrating BAT2206 is highly similar with Stelara® in patients with moderate to severe plaque psoriasis.
- In February 2023, Innovent Biologics announced that the first patient with moderate-to-severe plaque psoriasis had been successfully dosed in a Phase III clinical trial (CLEAR) of picankibart (IBI112), a recombinant anti-interleukin 23p19 subunit (IL23p19) antibody injection.
- In October 2023, Meiji Seika Pharma Co., Ltd. announced that positive findings from the Phase II clinical trial of ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, in patients with plaque psoriasis conducted in the United States and Canada (NCT05268016) were presented on 12 October at the European Association of Dermatology and Venereology (EADV) Congress 2023 held in Berlin.
Request a sample and discover the recent advances in psoriasis vulgaris treatment drugs @ Psoriasis Vulgaris Pipeline Report
The psoriasis vulgaris pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage psoriasis vulgaris drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the psoriasis vulgaris clinical trial landscape.
Psoriasis Vulgaris Overview
Psoriasis vulgaris is a long-lasting skin condition marked by the quick renewal of the outer skin layer, leading to the buildup of thick scales in areas prone to frequent injury or irritation. It is also referred to as chronic plaque psoriasis or plaque psoriasis, characterized by raised, reddish skin patches covered with silvery scales. This type of psoriasis is the most prevalent, affecting around 80-90% of individuals with the condition. Psoriasis itself is a diverse and lifelong skin disorder that appears in various forms such as plaque, flexural, guttate, pustular, or erythrodermic.
The development of psoriasis involves excessive skin cell growth and changes in how keratinocytes mature. Its root cause is a combination of genetic, immunological, and environmental factors. Specific environmental factors are believed to disturb the skin's immune system balance in people genetically predisposed to the condition. Some medications, like angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), antimalarials, lithium, and nonsteroidal anti-inflammatory drugs, have been linked to the onset or worsening of psoriasis.
Doctors typically diagnose psoriasis vulgaris by physically examining the skin, scalp, and nails for characteristic signs. They may inquire about the patient's health, medical background, family history, recent illnesses, and significant stress. Occasionally, a small skin sample might be needed for microscopic examination to exclude other skin conditions resembling psoriasis and to identify the specific type. However, a skin biopsy is rarely necessary for diagnosis.
Find out more about psoriasis vulgaris treatment drugs @ Drugs for Psoriasis Vulgaris Treatment
A snapshot of the Psoriasis Vulgaris Pipeline Drugs mentioned in the report:
| Drugs |